• ENGLISH
  • FRANCAIS
  • Services
    • Services Overview
    • Clinical Trial Operations
      • Protocol Development and Study Design
      • Feasibility and Study Start Up
      • Patient Recruitment
      • Project Management
      • Clinical Operations
      • Centralized Monitoring
      • Decentralized Clinical Trials (DCT)
      • Centralized eTMF
      • Medical Services
    • Regulatory and Drug Development Consulting
      • Clinical Strategy
      • Nonclinical
      • Chemistry, Manufacturing, and Controls (CMC)
      • Regulatory Affairs
      • GxP Strategy Consulting
      • Publishing and Submissions
      • Medical Writing
    • Government and Public Health Services
    • Biometrics
      • Biostatistics and Statistical Programming
      • Data Management
    • Clinical Pharmacology Modeling Simulation
      • Clinical Pharmacology Integrated Drug Development
      • Model Informed Dose & Drug Development (MIDD)
      • Pharmacometrics (PMx), Pharmacokinetics, Pharmacodynamics (PK/PD)
      • DMPK and Translational Discovery and Development
  • Therapeutic Expertise
    • Therapeutic Expertise Overview
    • By Subject
      • Oncology and Hematology
      • Rare Diseases and Orphan Drugs
      • Infectious Disease and Vaccine
      • Cell and Gene Therapy
      • Central Nervous System
      • Autoimmune and Inflammation
      • Allergy and Asthma
    • By Phase
  • Company
    • About Us
    • History
    • News
    • Events
    • Leadership
    • Mission, Vision, Values
  • Resources
    • Resource Library
    • Blogs
    • Case Studies
    • Podcasts
    • Webinars
    • White Papers
  • Careers
    • Careers Overview
    • Job Listings
    • CRA Academy and Fellows Program
  • Contact Us
    • Contact Us
    • Request for Proposal
  • ENGLISH
  • FRANCAIS
  • Services
    • Services Overview
    • Clinical Trial Operations
      • Protocol Development and Study Design
      • Feasibility and Study Start Up
      • Patient Recruitment
      • Project Management
      • Clinical Operations
      • Centralized Monitoring
      • Decentralized Clinical Trials (DCT)
      • Centralized eTMF
      • Medical Services
    • Regulatory and Drug Development Consulting
      • Clinical Strategy
      • Nonclinical
      • Chemistry, Manufacturing, and Controls (CMC)
      • Regulatory Affairs
      • GxP Strategy Consulting
      • Publishing and Submissions
      • Medical Writing
    • Government and Public Health Services
    • Biometrics
      • Biostatistics and Statistical Programming
      • Data Management
    • Clinical Pharmacology Modeling Simulation
      • Clinical Pharmacology Integrated Drug Development
      • Model Informed Dose & Drug Development (MIDD)
      • Pharmacometrics (PMx), Pharmacokinetics, Pharmacodynamics (PK/PD)
      • DMPK and Translational Discovery and Development
  • Therapeutic Expertise
    • Therapeutic Expertise Overview
    • By Subject
      • Oncology and Hematology
      • Rare Diseases and Orphan Drugs
      • Infectious Disease and Vaccine
      • Cell and Gene Therapy
      • Central Nervous System
      • Autoimmune and Inflammation
      • Allergy and Asthma
    • By Phase
  • Company
    • About Us
    • History
    • News
    • Events
    • Leadership
    • Mission, Vision, Values
  • Resources
    • Resource Library
    • Blogs
    • Case Studies
    • Podcasts
    • Webinars
    • White Papers
  • Careers
    • Careers Overview
    • Job Listings
    • CRA Academy and Fellows Program
  • Contact Us
    • Contact Us
    • Request for Proposal
  1. Home
  2. Services
  3. Clinical Pharmacology Modeling Simulation
  4. Model Informed Dose & Drug Development (MIDD)
  5. Dose Translation, Rationale, and Justification
    • Dose Translation, Rationale, and Justification
    • Bridging and Extrapolation Approaches
    • Modeling and Simulation

Dose Translation, Rationale, and Justification

  • Model Informed Dose & Drug Development (MIDD)
  • Dose Translation, Rationale, and Justification
  • Bridging and Extrapolation Approaches
  • Modeling and Simulation

Establishing the appropriate dosing regimens is critical to maximizing safety and efficacy for patients and clinical trial participants. Allucent’s pharmacologists and pharmacometricians are experts in dose translation, selection, and justification across all therapeutic areas, modalities, and stages of development.

Allucent partners with your team to build strategies and models tailored to guide your program’s dosing decisions. Even before your drug reaches the clinic, nonclinical modeling and simulation approaches are used to predict human PK and dose based on desired PD (safety and efficacy targets or outcomes) to inform candidate selection, formulation selection, other nonclinical studies, and establish an appropriate first-in-human (FIH) starting dose and dose range.  

Allucent’s pharmacometricians use modeling techniques to explore and/or evaluate how different dosing choices (e.g., dose amount, frequency, and duration) and patient variability affect drug concentrations and the relationships between drug concentration and desired or undesired responses to select appropriate doses for clinical trials, specific populations, and indications, as appropriate, for regulatory authority review.

Dose Translation, Rationale, and Justification Services: 

  • Calculating the clinical dose to inform:
    • candidate selection, product profile, therapeutic index, formulation selection, drug supply, cost of goods, dose range for toxicology studies, assay development, and drug-drug interaction potential
  • Translating in vitro, non-clinical PK/PD data, and published controlled clinical study results to clinical dose strategies
    • i.e., starting dose, dose escalations, dose cohorts, proof of concept and dose-ranging study designs, drug-drug interaction studies, etc.
  • Optimizing dose and dose frequency for specific populations
    • infants, children, pregnant and breast-feeding women, elderly, patients with renal or hepatic impairment, and more
  •  Providing comprehensive justification of the clinical dose(s) for indications, diverse patient characteristics, and various clinical scenarios for regulatory authority review

 

Contact Us

Let us partner with your team on bringing new therapies to light. Get in touch to get started.

CONTACT US

  • Services
    • Clinical Trial Operations
    • Regulatory and Drug Development Consulting
    • Government and Public Health Services
    • Biometrics
    • Clinical Pharmacology Modeling Simulation
  • Therapeutic Expertise
    • Oncology and Hematology
    • Rare Diseases and Orphan Drugs
    • Infectious Disease and Vaccine
    • Cell and Gene Therapy
    • Central Nervous System
    • Autoimmune and Inflammation
    • Allergy and Asthma
  • Company
    • About Us
    • News
    • Events
  • Privacy Policy
  • English
  • Francais

© 2023 Allucent. All rights

North American Headquarters
2000 Centregreen Way
Suite 300
Cary, North Carolina 27513
+1 919-361-2286

United Kingdom Headquarters
1st Floor, One Station Square,
Bracknell, Berkshire
RG12 1QB United Kingdom
T: +44 (0) 1344 891121
F: +44 (0) 1344 890335

European Headquarters
Stationsplein Noord-Oost 438
1117 CL Schiphol
The Netherlands
+31 20-4350-580